Abstract
Background In children, SARS-CoV-2 is usually asymptomatic or causes a mild illness of short duration. Persistent illness has been reported; however, its prevalence and characteristics are unclear. We aimed to determine illness duration and characteristics in symptomatic UK school-aged children tested for SARS-CoV-2 using data from the COVID Symptom Study, the largest citizen participatory epidemiological study to date.
Methods Data from 258,790 children aged 5-17 years were reported by an adult proxy between 24 March 2020 and 22 February 2021. Illness duration and symptom profiles were analysed for all children testing positive for SARS-CoV-2 for whom illness duration could be determined, considered overall and within younger (5-11 years) and older (12-17 years) age groups. Data from symptomatic children testing negative for SARS-CoV-2, matched 1:1 for age, gender, and week of testing, were also assessed.
Findings 1,734 children (588 younger children, 1,146 older children) had a positive SARS-CoV-2 test result and calculable duration of illness within the study time frame. The commonest symptoms were headache (62.2%) and fatigue (55.0%). Median illness duration was six days (vs. three days in children testing negative), and was positively associated with age (rs 0.19, p<1.e-4) with median duration of seven days in older vs. five days in younger children.
Seventy-seven (4.4%) children had illness duration ≥28 days (LC28), more commonly experienced by older vs. younger children (59 (5.1%) vs. 18 (3.1%), p=0.046). The commonest symptoms experienced by these children were fatigue (84%), headache (80%) and anosmia (80%); however, by day 28 the median symptom burden was two. Only 25 (1.8%) of 1,379 children experienced symptoms for ≥56 days. Few children (15 children, 0.9%) in the negatively-tested cohort experienced prolonged symptom duration; however, these children experienced greater symptom burden (both throughout their illness and at day 28) than children positive for SARS-CoV-2.
Interpretation Some children with COVID-19 experience prolonged illness duration. Reassuringly, symptom burden in these children did not increase with time, and most recovered by day 56. Some children who tested negative for SARS-CoV-2 also had persistent and burdensome illness. A holistic approach for all children with persistent illness during the pandemic is required.
Funding Engineering and Physical Sciences Research Council (EPSRC), National Institute for Health Research (NIHR), Medical Research Council (MRC), Zoe Global Limited, The Wellcome Trust, Alzheimer’s Society.
Evidence before this study SARS-CoV-2 in children is usually asymptomatic or manifests as a mild illness of short duration. However, anecdotal cases have raised concerns of prolonged illness in children, with no clear resolution of symptoms several weeks after onset, as is observed in some adults. How common this might be in children, the clinical features of such prolonged illness in children, and how it might compare with illnesses from other respiratory viruses (and with general population prevalence of these symptoms) is unclear.
Added value of this study We provide systematic description of COVID-19 in school-aged children. Our data, collected in a digital surveillance platform through one of the largest citizen science initiatives, show that long illness duration after SARS-CoV-2 infection in school-aged children does occur, but is uncommon. Only a small proportion of children have illness beyond four weeks; and the symptom burden in these children usually decreases over time. Most children resolve all symptoms by eight weeks, providing reassurance about long term outcomes. Importantly, symptom burden does not outnumber that observed in long illness due to causes other than SARS-CoV-2 infection.
Implications of all the available evidence Our results confirm that COVID-19 illness in children and adolescents is resolved in the community, after short duration, low symptom burden and with no need of hospitalization in most cases. Our findings also highlight that allocation of appropriate resources will be necessary for any child with prolonged illness, whether due to SARS-CoV-2 infection or other illness. Our study provides timely and critical data to inform discussions around the impact and implications of the pandemic on UK paediatric healthcare resource allocation.
Competing Interest Statement
CH, SS, KR, JCP are employees of Zoe Global Ltd. All other authors have nothing to declare.
Clinical Trial
This is not a clinical trial. Ethics approval for this study was granted by the KCL Ethics Committee REMAS ID 18210, review reference LRS-19/20-18210 and all participants (here, the proxy-reporting adult) provided consent.
Funding Statement
This work is supported by the Wellcome EPSRC Centre for Medical Engineering at Kings College London (WT 203148/Z/16/Z) and the UK Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guys & St Thomas NHS Foundation Trust in partnership with Kings College London and Kings College Hospital NHS Foundation Trust. Investigators also received support from the Medical Research Council (MRC) and British Heart Foundation, the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare, and the Wellcome Flagship Programme (WT213038/Z/18/Z). EM is funded by an MRC Skills Development Fellowship Scheme at KCL. CHS is supported by an Alzheimer's Society Junior Fellowship (AS-JF-17-011). ZOE Global supported all aspects of building and running the app and service to all users worldwide.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for this study was granted by the KCL Ethics Committee REMAS ID 18210, review reference LRS-19/20-18210 and all participants (here, the proxy-reporting adult) provided consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Equal contribution
Data Availability
Data collected in the COVID Symptom Study smartphone application are being shared with other health researchers through the UK National Health Service-funded Health Data Research UK (HDRUK) and Secure Anonymised Information Linkage consortium, housed in the UK Secure Research Platform (Swansea, UK). Anonymised data are available to be shared with researchers according to their protocols in the public interest (https://web.www.healthdatagateway.org/dataset/fddcb382-3051-4394-8436-b92295f14259).
https://web.www.healthdatagateway.org/dataset/fddcb382-3051-4394-8436-b92295f14259
